Loading...
Loading...
GLYC| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.3M |
| Gross Profit | -0.3M |
| Operating Expense | 9,813.5M |
| Operating I/L | -9,813.5M |
| Other Income/Expense | 0.6M |
| Interest Income | 611.0M |
| Pretax | -9.2M |
| Income Tax Expense | -0.0M |
| Net Income/Loss | -9.2M |
GlycoMimetics, Inc. is a clinical-stage biotechnology company specializing in the discovery and development of glycomimetic drugs to address unmet medical needs. Its lead product, uproleselan, an E-selectin inhibitor, is being developed in combination with chemotherapy for acute myeloid leukemia (AML) treatment, with a phase 3 trial for relapsed/refractory AML. The company is also developing GMI-1359 for bone and bone marrow cancer treatment, along with other programs such as GMI-1687 for vaso-occlusive crisis and galectin-3 antagonists. Collaborations with the National Cancer Institute and Apollomics (Hong Kong) Limited support its research and commercialization efforts.
